- Home
- AGIO vs CCEC Comparison
AGIO vs CCEC Comparison
Compare AGIO & CCEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | CCEC |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGIO | CCEC |
|---|---|---|
| Price | $27.43 | $22.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $37.63 | $25.50 |
| AVG Volume (30 Days) | ★ 791.9K | 7.6K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $75.68 | $20.75 |
| Revenue Next Year | $167.63 | $38.89 |
| P/E Ratio | ★ N/A | $4.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $14.09 |
| 52 Week High | $46.00 | $24.83 |
Technical Indicators
Market Signals| Indicator | AGIO | CCEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 47.59 |
| Support Level | $26.40 | $21.76 |
| Resistance Level | $29.49 | $23.76 |
| Average True Range (ATR) | 1.18 | 0.98 |
| MACD | -0.19 | -0.12 |
| Stochastic Oscillator | 14.64 | 34.24 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.